MAZE
$50.39
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE82...
Recent News
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum
Maze Therapeutics (MAZE), a clinical stage biopharmaceutical company focused on renal, cardiovascular and metabolic diseases, has recently drawn attention as investors consider its pipeline progress in relation to current trading levels. See our latest analysis for Maze Therapeutics. At a latest share price of $51.84, Maze Therapeutics has seen a 14.43% 7 day share price return and a 30.34% year to date share price return, while the 1 year total shareholder return is very large, indicating...
Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls
Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise spending and payments.
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return
What is driving interest in Maze Therapeutics right now? Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $46.01 and showing mixed short term moves, including a 1 day decline and a modest gain over the past week. See our latest analysis for Maze Therapeutics. For context, Maze Therapeutics has a 30 day share price return of 11.92% and a 90 day share price return of 41.44%, while its 1 year total shareholder return of 283.42% suggests strong...